Robert G. Gish, MD, is Medical Director of the Liver Transplant Program and Chief of the Division of Hepatology and Complex Gastroenterology at California Pacific Medical Center in San Francisco, California. He is Associate Clinical Professor of Medicine at the University of California in San Francisco and Clinical Professor at both University of Nevada Reno and Las Vegas. He completed a 4 year program in Pharmaceutical Science and his MD from University of Kansas School of Medicine. After completing his residency in Internal Medicine at the University of California, San Diego, he went on to complete a fellowship in Gastroenterology and Hepatology at the University of California, Los Angeles.
An internationally recognized liver specialist, Dr Gish has been widely acknowledged for both his clinical and research efforts. His scholarly and clinical work primarily focuses on the diagnosis and treatment of chronic hepatitis. Since completing his fellowship, he has been a key contributor to the evolving field of hepatitis B virus (HBV) and hepatitis C virus (HCV) research and treatment. Dr Gish was a major early contributor to the decipherment of methods for the detection of HCV in patients, and to characterizing the epidemiology and clinical presentation of this major pathogen in humans. He was involved in studies that ultimately led to the genotypic classification strategies and methods currently being used worldwide. Dr Gish has long contributed to the development of therapeutic strategies for HCV and he remains at the forefront of clinical research on new treatment modalities. His research on the detection, characterization, and treatment of HBV has been equally productive. Dr Gish has identified drug-resistant mutations and worked with other research scientists to identify HBV genotypes that have led to a better understanding of this major worldwide health problem.
National organizations devoted to the study and care of patients with liver disease and liver transplantation have widely benefited from Dr Gish’s participation and contributions, which have been integral to providing local responses to viral hepatitis and liver transplantation needs. He was named recipient of the “Salute to Excellence” award of the American Liver Foundation and served as Medical Director and as a member of the Board of Directors of the HCV Global Foundation. Dr Gish has served on national committees within the American Society of Transplant Physicians, American Association for the Study of Liver Diseases (AASLD), and the Liver and Intestinal Transplantation Committee of OPTN/UNOS (Organ Procurement and Transplant Network/United Network for Organ Sharing).
Among his contributions to the literature are more than 200 articles, book chapters, and monographs with over 80 citations in PubMed. According to the Institute for Scientific Information Citation Index, his work has been cited in over 2,000 publications. Dr Gish has been invited to present his work or to deliver plenary addresses over 200 times, and has been a prominent speaker at the AASLD and DDW annual meeting. In addition, he serves on the editorial board of five journals, is associate editor of two international journals, and conducts reviews for the leading peer-reviewed journals in the gastroenterology and hepatology fields.Dr Gish is the recipient of 100 research grant awards, most of which have been to develop and conduct clinical trials. These studies have led to the licensure of at least six different clinically effective antiviral therapies for HCV and HBV, including interferon, ribavirin, pegylated interferon, lamivudine, entecavir, and tenofovir.